Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?

Meral R, Celik Guler M, Kaba D, Prativadi J, Frontera ED, Foss-Freitas MC, Nachawi N, Broome DT, Lightbourne M, Brown RJ, Taylor SI, Oral EA

Diabetes care1 May 2025Cited by 13 (Europe PMC)

PMID40063619PMCIDPMC12034899DOI10.2337/dc24-2408PepBankPUB-40063619

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In patients with lipodystrophy, BMI fell after tirzepatide (median difference -1.7 kg/m2, P = 0.008).
In plain wordsIn people with lipodystrophy, BMI was lower after tirzepatide treatment. There was no placebo group.
Peptide
Tirzepatide
Outcome
DecreaseBMI change
Study
n = 17
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · median 8.7 monthsAs given in this study (human).
Measurements
Median difference in BMI
−1.7 kg/m2
after median 8.7 months
Source sentences
Summary
BMI (median difference, -1.7; range, -5.9 to 0.9 kg/m2; P = 0.008)
2 context sentences(design, population, supporting numbers)
Summary · context
An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies.
Summary · context
Seventeen patients received tirzepatide, 14 who had FPLD (aged 30-74 years; n = 12 female and 2 male).
Report a problemFND-4006361901
02HumanObservational studyEfficacy outcome
In patients with lipodystrophy, HbA1c fell after tirzepatide (median difference -1.1%, P < 0.001).
In plain wordsIn people with lipodystrophy, HbA1c, a blood sugar measure, was lower after tirzepatide treatment. There was no placebo group.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change
Study
n = 17
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · median 8.7 monthsAs given in this study (human).
Measurements
Median difference in HbA1c
−1.1%
after median 8.7 months
Source sentences
Summary
HbA1c (median difference, -1.1%; range, -6.3% to -0.1%; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies.
Summary · context
Seventeen patients received tirzepatide, 14 who had FPLD (aged 30-74 years; n = 12 female and 2 male).
Report a problemFND-4006361902
03HumanObservational studyEfficacy outcome
In patients with lipodystrophy, triglycerides fell after tirzepatide (median difference -65 mg/dL, P = 0.003).
In plain wordsIn people with lipodystrophy, blood triglycerides were lower after tirzepatide treatment. There was no placebo group.
Peptide
Tirzepatide
Outcome
DecreaseTriglyceride change
Study
n = 17
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · median 8.7 monthsAs given in this study (human).
Measurements
Median difference in triglycerides
−65 mg/dL
after median 8.7 months
Source sentences
Summary
triglycerides (median difference, -65 mg/dL [-0.73 mmol/L]; range, -3,820 to 43 mg/dL [-43.2 to 0.49 mmol/L]; P = 0.003)
2 context sentences(design, population, supporting numbers)
Summary · context
An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies.
Summary · context
Seventeen patients received tirzepatide, 14 who had FPLD (aged 30-74 years; n = 12 female and 2 male).
Report a problemFND-4006361903
04HumanObservational studyEfficacy outcome
In patients with lipodystrophy, total daily insulin requirements fell after tirzepatide (median difference -109 units/day, P = 0.002).
In plain wordsIn people with lipodystrophy, the daily insulin dose needed was lower after tirzepatide treatment. There was no placebo group.
Peptide
Tirzepatide
Outcome
DecreaseTotal daily insulin requirement change
Study
n = 17
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · median 8.7 monthsAs given in this study (human).
Measurements
Median difference in total daily insulin
−109 units/day
after median 8.7 months
Source sentences
Summary
total daily insulin requirements (median difference, -109; range, -315 to 0 units/day; P = 0.002)
2 context sentences(design, population, supporting numbers)
Summary · context
An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies.
Summary · context
Seventeen patients received tirzepatide, 14 who had FPLD (aged 30-74 years; n = 12 female and 2 male).
Report a problemFND-4006361904
05HumanObservational studySafety outcome
In patients with lipodystrophy who received tirzepatide, side effects were limited to benign gastrointestinal symptoms.
In plain wordsIn people with lipodystrophy who took tirzepatide, side effects were limited to mild stomach and gut symptoms.
Peptide
Tirzepatide
Outcome
Not applicableSide effects
Study
n = 17
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · median 8.7 monthsAs given in this study (human).
Source sentences
Summary
Side effects were limited to benign gastrointestinal symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies.
Summary · context
Seventeen patients received tirzepatide, 14 who had FPLD (aged 30-74 years; n = 12 female and 2 male).
Report a problemFND-4006361905
06HumanCase report or seriesEfficacy outcome
In three patients with rarer forms of lipodystrophy (atypical partial or acquired generalized), the abstract describes a robust response to tirzepatide without giving values.
In plain wordsIn three people with rarer forms of lipodystrophy, the abstract describes a strong response to tirzepatide but gives no values.
Peptide
Tirzepatide
Outcome
Not applicableResponse in rarer forms of lipodystrophy
Study
n = 3
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Three additional patients with rarer forms of lipodystrophy, also with robust response to tirzepatide, are also discussed (atypical PL, n = 1; acquired GL, n = 2; aged 35-64 years; all female).
2 context sentences(design, population, supporting numbers)
Summary · context
An observational cohort of patients with lipodystrophy who received tirzepatide clinically were tracked in the context of ongoing natural history studies.
Summary · context
Seventeen patients received tirzepatide, 14 who had FPLD (aged 30-74 years; n = 12 female and 2 male).
Report a problemFND-4006361906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.